Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

s release related July 16, 2009 for more information about the Phase I clinical trial.
  • In a double-blind test, for the purpose of conducting the clinical trial in a completely objective manner, the physicians performing the trial as well as the patients participating in the trial do not know if the substance administered to each individual is the drug being tested or the placebo.
  • The placebo is a substance that does not include the drug being tested (RK-023 in this case).
  • About R-Tech Ueno, Ltd.

    R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. The company's main product Rescula(R) eyedrop 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company. Rescula(R) eyedrop 0.12% that causes less topical and systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

        Stock Code: No.4573, Osaka Securities Exchange; Hercules
        Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
        Representative Director & President: Yukihiko Mashima
    
    
        Contact:
        Koji Nakamura,
        Business Management Department
        R-Tech Ueno, Ltd.
        Tel: +81-3-3596-8011
        e-mail: koji.nakamura@rtueno.co.jp
        URL: '/>"/>
    SOURCE R-Tech Ueno, Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
    2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
    3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
    4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
    5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
    6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
    7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
    8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
    9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
    10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
    11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
    (Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
    (Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
    Breaking Medicine Technology:Global Laparoscopy Devices Industry Report 2014 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
    (Date:9/16/2014)... activity monitors hold great promise in helping people ... increasingly sophisticated devices help the wearers improve their ... responses. This information is organized into companion computer ... large and quickly growing market for these devices, ... at Galveston analyzed 13 of these activity monitors, ...
    (Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
    (Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
    (Date:9/16/2014)... DC (PRWEB) September 16, 2014 Programs ... potentially yield hundreds of billions of dollars in savings ... report by the Commonwealth Fund. To help spur these ... seeking up to 10 collaborative groups from across the ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed to ...
    (Date:9/16/2014)... 16, 2014 Who:, The Pulmonary Hypertension ... Campus and Children’s Hospital Colorado are hosting ... country’s leading pulmonary hypertension association that works to find ways ... of the lungs that affects the functioning of the heart ... survivability is only 2.8 years. , What:, Colorado PH ...
    Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
    ... Push for More Charity Care After County,Assessor Reports ... CHICAGO, Nov. 8 Joined by union ... on Thursday,said the State and County should require ... justify their tax exemptions by providing more,charity care ...
    ... Adaptis, a business integration,provider focused exclusively on ... Inc., has purchased HealthASPex (HAX) through an,asset ... and PPO routing,services to Third Party Administrators ... http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) "Tela,s streamlined front-end ...
    ... and e-Health, a publication available in print and on-line by ... expand its content and frequency beginning in 2008; a new ... issue. , A new format ... enables more news, roundtable discussions, case studies, interviews with leaders ...
    ... topic of cancer prevention is covered widely in the ... information and complex scientific research that is not easily ... for Cancer Research (AACR) and Susan G. Komen for ... scientific research community and journalists who cover cancer science ...
    ... Make Breast Cancer ... Nov. 8 Washington State has the highest rate,of breast ... of Susan G. Komen for the Cure will host a ... policymakers to increase the budget for,screening programs for low-income women ...
    ... Develop a New Thrombectomy ... to Remove Clots in Blood Vessels, ST. PAUL, Minn., ... Dakota state lawmakers, with the support of Governor John Hoeven,and ... for Enova Medical Technologies, the University of North Dakota (UND),and ...
    Cached Medicine News:Health News:Charity Care Hospitals Told to Put Up or Pay Up in Wake of New Report 2Health News:Charity Care Hospitals Told to Put Up or Pay Up in Wake of New Report 3Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2Health News:Telemedicine publication expands coverage 2Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:North Dakota Grants Enova Medical Technologies a $2.5 Million Centers of Excellence Grant 2
    ... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
    ... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
    ... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
    ... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
    Medicine Products: